1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Dr Daniel Tillett, CEO of Race Oncology (ASX:RAC) shares the progress of its phase one trial for RC220, a treatment for solid tumours. He highlights the drug's potential to protect patients' cardiovascular systems while effectively targeting cancer cells. He explains the innovative trial involves combining RC220 with doxorubicin, marking a new frontier in cancer care.
Daniel says that the trial will be conducted at ten sites, including four in Australia, alongside locations in Hong Kong and South Korea. The trial considers genetic diversity, ensuring RC220's effectiveness across varied patient backgrounds. Race Oncology (ASX:RAC) aims to deliver a quick readout on efficacy to proceed with larger trials.
Daniel is optimistic about Race Oncology's (ASX:RAC) funding, with the trial fully financed and potential for further options. While optimistic about shareholder returns, he hopes for a stable environment to foster R&D growth. Despite US uncertainties, Race Oncology’s (ASX:RAC) global reach provides flexibility in navigating challenges.
